Startup Orchid bets on genetically selected babies

Imagine starting the process of in vitro fertilization (IVF) and discover that your clinic has a partnership with Orchid, a reproductive technology startup that offers DNA analysis of your embryos? This analysis allows you to choose which embryo has advantages for implantation.

The reproductive technology startup, which operates in the field of assisted reproduction, recently launched an innovative proposal: genome sequencing for embryos. Next, the showmetech presents details about the company's proposal and discussions around genetically selected babies, addressing ethical, scientific and social issues.

Orchid's proposal

A Orchid recently announced that it is offering whole genome sequencing for embryos, aiming to provide potential parents and their doctors with information that could make pregnancies healthier and more successful. The company is present in several large cities in the United States and offers health reports that consider 99% of the embryo's genome.

The ability to read more than 99% of an embryo's DNA is groundbreaking.

George Church, geneticist and chemist.

During the process, the startup sequences the embryo's genome and carries out an examination to find variants linked to more than 1.200 monogenic disorders, caused by a single genetic variant. Additionally, they analyze the risk of developing polygenic disorders, which are more difficult to predict due to the effects of multiple genes.

Although some researchers, such as Church, support the proposal, others are concerned about the Orchid and other companies that offer risk scores for polygenic diseases when it is not clear how accurate these data are.

Part of my concern is how sincere [Orchid] is in advising parents about the likely benefit of these procedures

Peter Kraft, professor of epidemiology at Harvard.

Although the startup shared information validating the technique used to sequence embryo genomes on the preprint server bioRXiv, it has not been confirmed that this information will result in healthier pregnancies or babies.

Noor Siddiqui, CEO e foundress da Orchid, disputes the idea that his company should not provide the genetic information it is capable of collecting to its customers.

How you use this information is really up to you, but it gives a lot more control and confidence to a process that, throughout history, has been left entirely to chance.

Noor Siddiqui, founder and CEO of Orchid

Siddiqui also states that the methods involved in the procedures of Orchid are detailed in a scientific article that has not yet been published. Shai Carmi, statistical geneticist da Hebrew University and affiliated with the company, explains that the whole genome technique makes it possible to detect mutations that neither parent carried and thus could not be detected by pre-pregnancy screening.

The new embryo selection method represents one of the greatest impacts of human genome sequencing to date, as emphasized George Church, teacher of genetics in Harvard. With this innovation, the company offers an advanced approach to assist parents in selecting embryos based on genetic information.

Critics raise ethical concerns about using these technologies to select for specific traits in embryos. Some researchers question the accuracy and validity of the results offered by Orchid.

These discussions highlight the importance of a comprehensive ethical and regulatory debate on the use of these emerging technologies in the field of assisted reproduction. Although they offer promises of potential benefits, it is essential to carefully consider the ethical, social and legal aspects involved in the genetic selection of embryos.

Differences between In Vitro Fertilization (IVF) and Preimplantation (PGT)

Infertility affects around 1 in 6 couples around the world, leading many people to turn to in vitro fertilization (IVF) as an alternative to conceiving. In this procedure, doctors fertilize eggs with sperm in the laboratory, resulting in the formation of embryos that will be transferred to the uterus to develop. In many cases, the eggs and sperm used come from individuals seeking to conceive, although donations are also common.

Although IVF increases the chances of success for infertile couples, there are no guarantees that the procedure will result in a successful pregnancy. Furthermore, it is an expensive process, with costs that can reach US$12.400 in the United States and between R$15.000 and R$20.000 in Brazil, and often requires multiple cycles before a pregnancy is achieved.

The genetic test pre-implantation (PGT) allows embryos to be examined before implantation in the uterus, identifying possible genetic variants that could cause pregnancy complications or increase the risk of genetic disorders in the baby. This offers prospective parents the opportunity to select embryos considered healthier based on limited information, as sequencing covers less than 1% of the embryo's genome.

Founder of Orchid uses genetic technology on herself

At 25 years of age, Noor Siddiqui launched his medical startup. Now that the genetic enhancement product is available, she has become one of its first customers. Although she and her husband are fertile, Siddiqui underwent IVF at Stanford, resulting in 16 candidates whose small representative fragments were sent to Orchid's laboratory.

To date, the recently opened company has 16 employees, US$12 million in funding and is present in more than 40 IVF clinics, with thousands of clients.

Currently, the Orchid is operating exclusively in IVF clinics in the United States. The cost per embryo for whole genome sequencing is $2.500 in addition to the standard fees charged by the IVF clinic. Converting to Brazilian reais, this value is equivalent to approximately R$12.667,01.

The reproductive technology startup's CEO emphasizes that the company aims to reduce the costs of genetic reporting as it moves forward, making this technology more accessible to a greater number of people seeking advanced fertility treatments.

Embryo selection raises ethical questions

Embryo selection raises a number of complex ethical questions. According to a recent survey by Harvard University, about two-thirds of Americans would consider undergoing IVF to access this form of genetic screening, while three-quarters express concerns that such tests may represent a form of eugenia, seeking genetic improvement similar to that advocated by the Nazis in the 20th century.

The use of human prenatal genetic testing has been widely implemented for decades. However, the use of genetic screening at the preimplantation stage along with IVF is controversial. Although it is conventionally used to prevent the selection of embryos with Mendelian abnormalities, using PGT to facilitate embryo gene editing is prohibited.

Future parents, by choosing embryos without genetic risk, theoretically have the option of creating a child with more intelligence, strength or beauty. O ACMG, however, warns that the scores related to these screenings can be inaccurate and require dangerous procedures. Although his justification is medically focused, it does not provide sufficient ethical guidance if medical/scientific obstacles are to be overcome.

There are several concerns with the use of preimplantation genetic screening. For example, the data used is often based on research populations, such as white Europeans, and may not be applicable to the cultural diversity of the market. Furthermore, the risks are not purely genetic and can be highly influenced by unpredictable external factors.

The ACMG invites reflection from the ethical and legal communities, recognizing that its review did not address the relevant concerns raised. The introduction of this technology to select so-called designer babies is seen as ethically questionable by many, given the lack of a specific structural basis for determining what is ethical in this context.

Companies promote their services directly to consumers and promise 'advanced embryo screening' for a variety of conditions. There are significant concerns that make such claims suspect and the introduction of this technology for embryo selection ethically questionable.

Alex Polyakov, Clinical Associate Professor, Faculty of Medicine at the University of Melbourne

From this perspective, companies that offer advanced genetic screening of embryos directly to consumers raise significant concerns. Many bioethicists oppose these practices, such as Julien Savulescu, which previously advocated for parents to choose the “best” children, but now limits its support to parents who use IVF due to infertility.

The debate over the ethics of embryo selection is reminiscent of the film's plot Gattaca, which explores a dystopian future in which the State controls aspects of social life and genetic quality, resulting in new forms of prejudice and social divisions based on genetic caste. In the film, genetics is portrayed as a science of power, allowing parents to manipulate genes to produce children with desired characteristics.

Sources: Social media coordinator, Wired, Freethink, Boston Globe, Acsh

See also:

reviewed by Glaucon Vital in 12 / 4 / 24.